How many of your moderate to severe acute pain patients are taking other medications?

The complexity of CYP450 PK drug-drug interactions

Common concomitant prescription drugs that may affect or are metabolized by the CYP450 pathway¹

67% of opioid patients take at least one other nonopioid prescription drug²*

Prescribing a CYP450-metabolized opioid with a CYP450-metabolized concomitant drug may complicate treatment decisions and drug regimens³

• May increase or decrease the efficacy of a CYP450-metabolized concomitant drug
• May increase or decrease opioid effect

* From a 3-month analysis of prescription data from 20,000 retail pharmacies

OPANA: No known CYP450 PK drug-drug interactions at clinically relevant doses⁴

• As demonstrated in in vivo and in vitro studies

Practical solution for moderate to severe acute pain patients

• No dose adjustments required for concomitant medications metabolized via the CYP450 pathway
• May help lessen the complexities of managing pain patients on multiple CYP450-metabolized medications

OPANA, like all opioid analgesics, should be started at 1/3 to 1/2 of the usual dose in patients who are concurrently receiving other CNS depressants including sedatives or hypnotics, general anesthetics, phenothiazines, tranquilizers, and alcohol, because respiratory depression, hypotension, and profound sedation or coma may result. No specific interaction between oxymorphone and monoamine oxidase inhibitors has been observed, but caution in the use of any opioid in patients taking this class of drugs is appropriate.